Hair loss treatments like Minoxidil, finasteride, and potential mRNAtherapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNAtherapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
Oral minoxidil is effective for hair loss and unlikely to significantly affect collagen synthesis, making it a safe option without causing premature skin aging. Users report positive hair regrowth without noticeable skin aging.